Scientists devise targeted therapy strategy for rare form of childhood cancer

	Tweet

By “distracting” cancer proteins from their usual activity, scientists at Dana-Farber Cancer Institute and Brigham and Women’s Hospital have caused cells in a rare, lethal form of cancer to begin behaving like normal cells—one of the longest-standing, and most rarely achieved, goals of cancer research. The study’s findings are published online by the journal Cancer Research and will appear later in a print issue.

When the approach was tested in a child with an advanced case of the malignancy, known as NUT midline carcinoma (NMC), it slowed the course of the disease for several months. That result, in a cancer for which there are no other effective treatments, is a powerful impetus for making the new therapy available to patients in clinical trials, the authors assert.

“NUT midline carcinoma arises people of all ages, but predominantly in children and young adults,” explained the study’s senior co-author, James Bradner, MD, of Dana-Farber. “It usually originates in the chest, sometimes in the head or neck, and is often mistaken for other types of cancer. Traditional therapy involves surgery, radiation, and chemotherapy, but even in combination these approaches don’t work well: most patients live only about nine and a half months after diagnosis. As we’ve learned more about the molecular basis of the disease, we’ve begun to be able to devise therapies against it.”

The cause of the disease was discovered by Christopher French, MD, a senior author of the study from Brigham and Women’s Hospital. It results from a “translocation” in which two genes from different chromosomes stick together and give rise to an abnormal, fused protein called BRD4-NUT. While Bradner and his colleagues have subsequently developed and studied compounds that target BRD4-NUT directly, the newly published study involves a more oblique approach.

Researchers discovered that BRD4-NUT causes cells to become cancerous by attaching to DNA’s packing material within the nucleus—a band of proteins known as histones, part of the machinery for switching genes on and off. BRD4-NUT essentially locks down the machinery’s control panel, preventing changes that allow cells to develop into mature, stable, slow-growing adults, leaving them in a state of perpetual, hyperactive youth.

To interfere with BRD4-NUT’s affinity for histones, French and Bradner tried a diversionary tactic. They treated NMC cells with a substance called an HDAC (histone deacetylase) inhibitor, which creates competing binding sites for BRD4-NUT throughout the nucleus. The hope was that, like a burglar who bypasses one house for the promise of a bigger prize in another, the HDAC inhibitor would lure BRD4-NUT away from certain locations in the genome.

In laboratory experiments, they found that NMC cells treated with an HDAC inhibitor turned into ordinary, non-dividing skin cells—a process known as “differentiation,” which has been a central goal of cancer research for well over half a century. In studies with animals engrafted with NMC tissue, animals treated with HDAC inhibitors had slower-growing tumors and lived longer than those who were not treated.

“These findings provided convincing evidence that we’ve uncovered a key mechanism by which BRD4-NUT prevents cell differentiation,” said Bradner. The results established the rationale for the first, prospective clinical trial of the HDAC inhibitor in a single patient with NMC. A Food and Drug Administration-approved inhibitor was prescribed to a child suffering from extensive NMC, leading to positive results after five weeks of therapy: PET scans showed the tumor was markedly less active than at the start of therapy. Although the patient eventually succumbed to the disease, the response to the drug heartened investigators on the potential of this approach. Dana-Farber’s Chief of Staff, Stephen Sallan, MD, co-led the clinical study.

The inspiration for this approach came from earlier research by French. About five years ago, he was investigating the effect of HDAC inhibitors on cell memory—the ability of cells to “remember” the type of cell they are as they divide. “HDAC inhibitors can alter cell memory,” French explained. “We hypothesized that treating NMC cells with these inhibitors would change the cells’ memory and modify their identity. What happened was that the cells remembered what type of cell they initially were and switched back to being normal skin-like cells. BRD4-NUT, it turns out, interferes with cell memory. Blocking the protein with HDAC inhibitors restores that memory.”

The discovery remained an interesting scientific “epiphany,” French said, until he met Bradner, sparking the idea of using it as the basis for a potential treatment for NMC. According to French, the new study marks the first time scientists have therapeutically caused a carcinoma—a cancer of cells lining an organ or tissue—to differentiate.

“The inhibitor used in the patient described in this study was a first-generation agent, and we’re optimistic that future versions will be both more effective and easier for patients to tolerate,” Bradner said. “To our knowledge, this study represents the first time a targeted drug has demonstrated anti-cancer activity against this devastating tumor. The same approach may prove beneficial against other cancers as well.”

###

The paper’s first author is Brian Schwartz, PhD, formerly a postdoctoral fellow at Brigham and Women’s. In addition to Bradner, French and Sallan, the other authors are Matthias Hofer, MD, Michael Cameron, Tan Ince, MD, PhD, Jon Aster, MD, PhD, and Elin Agoston, PhD, Brigham and Women’s; Amanda Christie, Katherine Janeway, MD, Madeleine Lemieux, PhD, and Andrew Kung, MD, PhD, Dana-Farber; Daniel Bauer, MD, PhD, Sara Vargas, MD, and Antonio Perez-Atayde, MD, Children’s Hospital Boston; Nathan West, Harvard Medical School; and Nicolas Reynoird, PhD, and Saadi Khochbin, PhD, Institut National de la Sante et de la Recherche Medicale, Grenoble, France.

The study was funded by a Nodal Research Award from the Dana-Farber/Harvard Cancer Center.

Dana-Farber Cancer Institute (http://www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women’s Hospital as Dana-Farber/Brigham and Women’s Cancer Center and it provides pediatric care with Children’s Hospital Boston as Dana-Farber/Children’s Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.

Brigham and Women’s Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. BWH is the home of the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 900 physician-investigators and renowned biomedical scientists and faculty supported by more than $ 537 M in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses’ and Physicians’ Health Studies and the Women’s Health Initiative.

###

Contact: Bill Schaller

617-632-5357
Dana-Farber Cancer Institute

RELATED STORIES:
Cancer Risks for Urban African-American Women Grow as Healthy Diets Become More Difficult to Maintai   Novel Anti-Cancer Mechanism Found in Long-Lived Rodents   Gene Therapy Anti-cancer Work Featured in Scientific American   Genetic Risk Factor Found for Head and Neck Cancer in Smokers   Researchers discover critical process in cancer treatment   Study Helps Explain Fundamental Process of Tumor Growth   Preventing cancer without killing cells   Simple test could hold key to early diagnosis of cancers   Cannabis ingredient can help cancer patients regain their appetites and sense of taste   Chemical in red wine, fruits and vegetables stops cancer, heart disease, depending on the dose   Cancer Gene Drives Pivotal Decision in Early Brain Development   Targeting cholesterol may help slow glioblastoma   Access to cancer care unequal across Europe   Dieting may not help cancer patients   Aggressive cancer treated successfully in mice   Cancer Cells Need Normal, Non-mutated Genes to Survive   Genome study shows what cancers have in common   American Cancer Society report details cancer prevention efforts   Evidence strengthens link between NSAIDs and reduced cancer metastasis   Factors that enhance autonomy of cancer patients   How cancer cells loose their (Circadian) rhythm   Study shows promise for new cancer-stopping therapy

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]